New hope for HIV patients with aggressive lymphoma: early trial launches
NCT ID NCT07649304
First seen Jun 27, 2026 · Last updated Aug 14, 2026 · Updated 4 times
Summary
This early-phase trial will test the safety and feasibility of adding the experimental drug glofitamab to standard chemoimmunotherapy (R-CHOP) in 15 people newly diagnosed with HIV-associated large B-cell lymphoma. Glofitamab is a bispecific antibody that helps the immune system attack cancer cells. The main goal is to see if at least 12 out of 15 participants can complete four full cycles of treatment without major issues.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- glofitamab plus R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone)
- What this could lead to
- If this combination proves safe and feasible, it could lead to a new treatment option for people with HIV-associated large B-cell lymphoma, potentially improving outcomes in this underserved population.
- What could go wrong
- This is a very early phase 1 trial with only 15 participants, so results may not apply to everyone. The combination may cause serious side effects like cytokine release syndrome or infections, and it is not yet known if it works better than standard care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AIDS-RELATED DIFFUSE LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a targeted drug boost standard chemo for an aggressive lymphoma?
- New drug aims to lock in remission for rare lymphoma
- New cocktail aims to tame aggressive lymphoma in the very elderly
- Scientists seek tissue samples to unlock HIV-Cancer mysteries
- New 'In-Body' CAR-T therapy takes aim at Hard-to-Treat lymphoma
- Gene therapy takes on HIV and cancer in one shot